Dimerix Limited announced an update for their two Phase 2 clinical trials, including the outcome of the first independent safety review for both trials. An independent Safety Review Committee, comprised of global experts in renal clinical research, has held two pre-planned meetings to review safety data from the patients enrolled in both the Phase 2a ACTION study in FSGS and the Phase 2 ACTION study in Diabetic Kidney Disease. The Committee did not identify any safety concerns in patients administered DMX-200 and unanimously recommended that the study continue as planned with the next meeting of the Committee to be held at the end of the study. The FSGS study completed recruitment in July 2019, with the last patient dosed in September 2019 following final protocol screening. The study remains on track to complete final patient dosing in June 2019, with top line data anticipated shortly thereafter. The Diabetic Kidney Disease study completed recruitment in September 2019, with the last patient dosed in January 2020 following final protocol screening. The study has successfully dosed an additional 5 patients, totalling 45 patients dosed with DMX-200, to ensure a study completion population of N=40 required for adequate statistical powering. Final patient dosing is scheduled for July 2020, with top line data anticipated shortly thereafter (previously anticipated Quarter 2).